

# Review of: "Hepatoprotective Effect of the Ursolic Acid-Oleanolic Acid Mixture Administered Intragastrically in Mice with Liver Damage Induced by Anti-TB Drugs"

Chernet Tafere

Potential competing interests: No potential competing interests to declare.

In the introduction part, you have provided a vast description of TB and anti-TB drugs, which was not the main objective of the study. You are not supposed to give all this introduction about TB as it's not your main objective. You'd better give an introduction to liver disease, its impact both regionally and globally, and show that there are no effective medications to treat the condition. Therefore, your work has the capacity to solve this problem.

Your problem statement must emphasize the scarcity of Hepatoprotective drugs.

Are the drugs withdrawn from the market? - In paragraph 3 of your introduction section, you have included a statement that reads, "the latter being one of the main causes of withdrawing drugs from the market."

Does your UA/OA mixture only help in protecting against liver problems caused by anti-TB drugs?

## Method section

Why did you choose 10 and 20 mg/kg as cut-off values? How did you select these points?

In a volume <10 mL/kg - what does this mean? You have to state the exact figure.

Why only male Balb/C mice? Why not the females?

You have used only 3 mice per group, but most scientists use ten mice per group as a rule of thumb ( $n = 10$  valid animals in each experimental group (<https://encr.pw/y4XWt>)).

## Discussion

How do you compare Gutiérrez-Rebolledo's research, which used 100 and 200 microgram doses, with your 10 and 20 mg/kg? In addition, in your study, the UA/OA mixture favored body weight gain, but in the study by Gutiérrez-Rebolledo, it prevented steatosis.

Moreover, if the UA/OA mixture was used by the researcher mentioned above, what is new about your study?